All news

An award agreement required a Bicycle Therapeutics (BCYC) officer to sell 1,572 and 242 shares for taxes.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Bicycle Therapeutics (BCYC) Chief Product & Supply Chain Officer Michael Charles Ferguson Hannay sold 1,572 ordinary shares on October 2, 2026, and 242 shares on October 5, 2026. These transactions were mandated by his award agreement to cover statutory tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs), rather than being discretionary sales. The sales were executed at weighted average prices of $3.47 and $3.57 per share, respectively.

Read original source

BCYC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.